AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37303683
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel and rt-PA intravenous thrombolytic therapy
Trial: 37304432
Drug: Fluvoxamine (FLV)
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (FLV) treatment for 2 months
Trial: 37304846
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron and folic acid (WIFA) supplementation and menstrual hygiene management (MHM) support for girls
Trial: 37305080
Drug: Starch thickened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch thickened formula with reduced lactose content, probiotics and prebiotics, administered for 30 days.
Trial: 37305429
Drug: Pioglitazone hydrochloride
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone hydrochloride and metformin hydrochloride
Trial: 37305429
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride
Trial: 37306039
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor monotherapy after 1-3 months of DAPT
Trial: 37306107
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg orally on Days 1-21 and ganitumab 18 mg/kg intravenously on Days 1 and 15 of a 28-day cycle.
Trial: 37306107
Drug: Palbociclib 100
RxNorm normalized name: palbociclib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 100 mg daily for 21 days (after dose reduction due to DLTs).
Trial: 37306128
Drug: Pill coverage
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Covera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill coverage
Trial: 37306288
Drug: BAY1128688 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 (3, 30, or 90 mg once daily or 60 mg twice daily for 14 days)
Trial: 37306288
Drug: BAY1128688 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 (60 mg once or twice daily for 28 days)
Trial: 37306874
Drug: Seeking Safety
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seeking Safety (integrated treatment for gambling and PTSD)
Trial: 37306874
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy for Pathological Gambling (for gambling alone)
Trial: 37307001
Drug: Mifepristone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 10 mg orally once a day for 12 weeks
Trial: 37307005
Drug: Add-on Rehmannia-6-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on Rehmannia-6-based Chinese medicine treatment for 48 weeks
Trial: 37307005
Drug: Add-on Rehmannia-6-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on Rehmannia-6-based Chinese medicine treatment
Trial: 37307232
Drug: Dexmedetomidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.6 μg kg -1 bolus followed by 0.4 μg kg -1 h -1 maintenance until dural closure)
Trial: 37307514
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by Nivolumab 3 mg/kg once every 2 weeks for ≤24 months
Trial: 37307514
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus Ipilimumab followed by Nivolumab monotherapy
Trial: 37307528
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg q.d.)
Trial: 37308133
Drug: Antibiotics (C1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (C1 group)
Trial: 37308133
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (C2 group)
Trial: 37308251
Drug: Y-2 sublingual
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-2 sublingual tablet
Trial: 37308342
Drug: Dasatinib 50
RxNorm normalized name: dasatinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 50 mg daily
Trial: 37308396
Drug: cfDNA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cfDNA level at diagnosis ≥ or <30 ng/mL and presence or not of KRAS-mutated ctDNA at D28
Trial: 37308490
Drug: JMT101 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT101 plus osimertinib 160 mg
Trial: 37308679
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for SUD
Trial: 37308751
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of once-weekly insulin icodec
Trial: 37308751
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose of once-weekly insulin icodec
Trial: 37308751
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of once-daily insulin glargine U100
Trial: 37308751
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose of once-daily insulin glargine U100
Trial: 37308905
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid infusion group (Ringer's lactate solution, maintaining PPV within 6-9%)
Trial: 37308905
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid infusion group (maintaining PPV within 13-16%)
Trial: 37308969
Drug: Active PEMF
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PEMF treatment and eccentric exercise
Trial: 37308969
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment and eccentric exercise
Trial: 37308971
Drug: Xentuzumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xentuzumab (1000 mg weekly intravenous infusion) with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Trial: 37308971
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Trial: 37309006
Drug: Compassion-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassion-focused therapy (CFT) for 12 weeks
Trial: 37309193
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg (DW1903) daily for 2 weeks
Trial: 37309193
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg (DW1903R1) daily for 2 weeks
Trial: 37309696
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency (ID) defined as serum ferritin < 100 μg/L or ferritin 100-299 μg/L with transferrin saturation < 20%.
Trial: 37310391
Drug: BNT162b2 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on anti-CD20
Trial: 37310391
Drug: BNT162b2 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on fingolimod
Trial: 37310391
Drug: BNT162b2 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on other treatments
Trial: 37310391
Drug: BNT162b2 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 primary and booster vaccination in MS patients on other treatments
Trial: 37310781
Drug: Digital training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital training (DT) course with weekly individualized coaching
Trial: 37310877
Drug: Increased adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Increased adalimumab dose intervals
Trial: 37310877
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing interval
Trial: 37311468
Drug: Luspatercept (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luspatercept (1.0 mg/kg body weight subcutaneously every 3 weeks, titrated up to 1.75 mg/kg)
Trial: 37311694
Drug: Polyethylene glycol-coated
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-coated patch
Trial: 37311722
Drug: Danuglipron (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron (200 mg BID)
Trial: 37311722
Drug: Danuglipron (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron (low [5-mg] or high [10-mg] starting dose, escalating to 80, 120 or 200 mg BID)
Trial: 37312053
Drug: HYDRA proton-
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYDRA proton- and photon radiotherapy (40 Gy elective dose, 55 Gy simultaneous integrated boost, 59 Gy focal boost)
Trial: 37312054
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of anti-PD-1 immunotherapy with avelumab
Trial: 37312086
Drug: non-standard targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-standard targeted therapy based on potentially actionable molecular alterations or biomarkers
Trial: 37312165
Drug: 2 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Trial: 37312165
Drug: 4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Trial: 37312233
Drug: Mepolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (300 mg subcutaneously every 4 weeks)
Trial: 37313403
Drug: Toripalimab plus
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab plus chemotherapy (TC)
Trial: 37313403
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (PC)
Trial: 37314165
Drug: Idarucizumab (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (specific dabigatran reversal agent)
Trial: 37314165
Drug: Andexanet alfa
RxNorm normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Andexanet alfa (for Xa inhibitors apixaban and rivaroxaban)
Trial: 37314244
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g bolus before hospital admission, followed by 1 g infusion over 8 hours)
Trial: 37314501
Drug: Neratinib 160
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 160 mg daily with trametinib 1 mg, 5 days on and 2 days off
Trial: 37314501
Drug: Neratinib 160
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 160 mg daily with trametinib 1 mg daily (DL1)
Trial: 37315268
Drug: Daratumumab, low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd)
Trial: 37315268
Drug: Carfilzomib, lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide, or lenalidomide, dexamethasone, and cyclophosphamide (MyeXI treatment)
Trial: 37315558
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular GRAd-COV2 administration
Trial: 37315558
Drug: Second administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second administration of GRAd-COV2
Trial: 37315558
Drug: Two vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two vaccine injections
Trial: 37315579
Drug: CP-506 with
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CP-506 with single dose irradiation
Trial: 37315590
Drug: Vortioxetine (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (initiated at 5 mg/day, up-titrated to 10 mg/day at day 8, flexible dosing thereafter [5-20 mg/day])
Trial: 37315924
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention of DHA-rich fish oil (1.1 g/d DHA and 0.4 g/d EPA) and cocoa flavanols (500 mg/d flavan-3-ols)
Trial: 37316311
Drug: Exenatide as
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide as an adjunct to nicotine patches
Trial: 37316789
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of General Anesthesia and Regional Anesthesia
Trial: 37316847
Drug: Dapagliflozin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin therapy
Trial: 37317022
Drug: guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 200 mg SC every 4 weeks through Week 36
Trial: 37317022
Drug: guselkumab 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 1200 mg IV for 12 weeks, then switched to guselkumab 200 mg SC every 4 weeks from Weeks 12 through 36
Trial: 37317022
Drug: placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 12 weeks, then re-randomized to guselkumab 200 mg SC every 4 weeks or guselkumab 100 mg SC at specified weeks
Trial: 37317993
Drug: Buparlisib (BKM120)
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (BKM120) monotherapy
Trial: 37318085
Drug: Avatrombopag (AVA)
RxNorm normalized name: avatrombopag
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avatrombopag (AVA) at a starting dose of 20 mg/d, titrated to a maximum of 60 mg/d
Trial: 37318116
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)
Trial: 37318116
Drug: ICS/LABA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA + long-acting muscarinic antagonist (LAMA)
Trial: 37318116
Drug: LAMA monotherapy
RxNorm normalized name: Lama palagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAMA monotherapy
Trial: 37318116
Drug: ICS-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS-containing therapy
Trial: 37318349
Drug: Talazoparib 1
RxNorm normalized name: talazoparib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib 1 mg once daily for 24 weeks
Trial: 37318379
Drug: Tucatinib in
RxNorm normalized name: Product containing tucatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib in combination with Trastuzumab
Trial: 37318469
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infiltration along the nephrostomy tract (20 mL)
Trial: 37318707
Drug: LipiFlow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow treatment prior to cataract surgery
Trial: 37318707
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LipiFlow treatment prior to surgery)
Trial: 37318707
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group after crossover (received LipiFlow treatment)
Trial: 37318750
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg Q2W
Trial: 37318808
Drug: Escitalopram, Sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, Sertraline, or Venlafaxine extended-release (1:1:1 randomization)
Trial: 37319244
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg modified-release prednisone
Trial: 37319432
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg IV every 3 weeks for up to 8 cycles after ASCT.
Trial: 37319438
Drug: Oral Octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Octreotide Capsules (OOC)
Trial: 37319438
Drug: Transitioning from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transitioning from injectable somatostatin receptor ligands (iSRLs) to Oral Octreotide Capsules (OOC)
Trial: 37319437
Drug: Abatacept (IV)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept (IV) with a target trough of 10 μg/mL and higher Ctrough_1 (≥39 μg/mL)
Trial: 37319437
Drug: Abatacept (IV)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept (IV) with Ctrough_1 <39 μg/mL
Trial: 37321663
Drug: Intratumoral T4
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratumoral T4 immunotherapy (CAR-T cells)
Trial: 37322121
Drug: Therapies matched
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies matched to genomic alterations in 27 substudies
Trial: 37322274
Drug: IV-golimumab 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-golimumab 2 mg/kg at week 0, week 4, then every 8 weeks
Trial: 37322367
Drug: Sugemalimab plus
RxNorm normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab plus chemotherapy (1,200 mg every 3 weeks)
Trial: 37322482
Drug: Latozinemab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latozinemab (single infusion)
Trial: 37322482
Drug: S15JG (anti-sortilin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S15JG (anti-sortilin antibody)
Trial: 37322511
Drug: Bipolar haemostatic
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bipolar haemostatic forceps (HemoStat/Pentax®) as experimental therapy (ET)
Trial: 37322511
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ST) using haemoclip + / - epinephrine injection
Trial: 37322538
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (3 g of probiotic preparation including eight bacterial strains)
Trial: 37322538
Drug: Prebiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic supplementation (5 g of oat bran)
Trial: 37323059
Drug: GSK2831781 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 450 mg intravenously (IV)
Trial: 37323099
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg orally once a week)
Trial: 37324622
Drug: MEDI-app (smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-app (smartphone app with alarm for drug intake, visual confirmation of drug administration, medication intake history)
Trial: 37324622
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (conventional treatment)
Trial: 37325226
Drug: Enhanced External
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced External Counter Pulsation (EECP) therapy
Trial: 37325545
Drug: Amsterdam Instrumental
RxNorm normalized name: AE-aspergillus amsterdami
DrugBank: Eurotium amstelodami (DB15526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q)
Trial: 37325545
Drug: Alzheimer's Disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Trial: 37325662
Drug: Control (23-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (23-valent pneumococcal polysaccharide vaccine and inactivated hepatitis A vaccine)
Trial: 37325860
Drug: afamitresgene autoleucel
RxNorm normalized name: Afamitresgene autoleucel
DrugBank: Afamitresgene autoleucel (DB18592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: afamitresgene autoleucel (afami-cel) therapy after low-dose radiotherapy (LDRT) at 5.6 Gy/4 fractions to the liver
Trial: 37325860
Drug: low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose radiotherapy (LDRT)
Trial: 37325931
Drug: Triple-negative receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-negative receptor subtype
Trial: 37326322
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (1.62% daily, adjusted to maintain testosterone levels between 350 and 750 ng/dL)
Trial: 37326322
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (1.62% daily)